Strategic Partnership to Boost Cardiac Care in Switzerland
Fort Mill, S.C. — Catheter Precision, Inc. (VTAK - NYSE/American), a pioneering medical device company dedicated to advancing cardiac interventions, has officially entered into a distribution agreement with FuMedica AG. This collaboration aims to introduce the innovative LockeT suture retention device to healthcare facilities across Switzerland.
The LockeT device represents a significant advancement in securing vascular access sites following cardiac procedures. Its design is user-friendly, which not only enhances the closure process but also reassures medical professionals relying on its performance in high-stakes environments like electrophysiology labs.
Why FuMedica AG?
FuMedica AG, headquartered in Muri, is renowned for its expertise in distributing cutting-edge medical technologies. Their well-established reputation in the realms of cardiology, surgery, and intensive care ensures that Catheter Precision’s LockeT device will be in reliable hands as it enters the market.
The strong relationships FuMedica has built with Swiss healthcare providers, coupled with their commitment to exceptional clinical support, make them an ideal partner for this initiative.
Voices from Catheter Precision
“This agreement signifies an important step in our European growth strategy,” commented Fatih Ayoglu, Sales Manager EMEA & APAC at Catheter Precision. He emphasized that FuMedica’s comprehensive understanding of the market and focus on quality complements their mission to provide effective tools that enhance patient outcomes. “We are confident that LockeT will be warmly received in the Swiss cardiac care community,” he added.
Catheter Precision’s decision to partner with FuMedica showcases the company’s dedication to innovating cardiac healthcare solutions globally.
Understanding the LockeT Device
LockeT is specially designed to aid in the closure of wounds created by percutaneous venous punctures. As a Class 1 device registered with the FDA, it has also achieved CE Mark approval, validating its safety and effectiveness for use across Europe.
About Catheter Precision
Catheter Precision is at the forefront of developing transformative technologies aimed at improving the treatment of cardiac arrhythmias. Collaborating closely with medical professionals, the company prioritizes innovation and is focused on crafting products that elevate the standard of care in electrophysiology.
About FuMedica AG
As a key player in the Swiss medical device distribution landscape, FuMedica AG specializes in delivering premium quality equipment across various medical fields. Their passion for clinical excellence and support for customers solidifies their position as an essential partner in advancing healthcare solutions.
Frequently Asked Questions
What is the purpose of the LockeT device?
The LockeT suture retention device simplifies and secures the closure of vascular access sites after cardiac procedures.
Who is Catheter Precision?
Catheter Precision, Inc. is a US-based medical device company focused on developing innovative solutions to treat cardiac arrhythmias.
What role does FuMedica AG play in this agreement?
FuMedica AG will distribute the LockeT device across Switzerland, leveraging their established healthcare relationships and expertise.
Why is this partnership significant?
This partnership is a critical step in Catheter Precision’s European expansion strategy, enhancing cardiac care in Switzerland.
Where can I find more information about these companies?
For further details, you can contact Catheter Precision’s investor relations directly via their provided email.
